Karl Ruping is the founder and CEO of Tiba Biotech, a Cambridge, Massachusetts company developing biodegradable nanoparticle delivery systems for RNA vaccines and therapeutics. He also runs incTANK Ventures, a seed fund spun out of MIT and Boston-area research labs, and sits at Harvard's Asia Center as an associate working on international patent policy. Lawyer, computational scientist, financier, and operator wrapped into one resume.
Gene Dolgoff is the founder, CEO, CTO, and Chairman of Holobeam Technologies, a Long Island biotech building holographic tools to detect and treat cancer. He has been making holograms since 1964, holds over 65 patents worldwide, built the world's first LCD projector, and consulted with Gene Roddenberry on the concept that became the Star Trek Holodeck. Today his company is developing Holographic Energy Teleportation (HET), advanced nanoparticles, and a new class of MRI imaging - aiming, in his words, to teleport energy through the body to kill cancer cells.

Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.
NVIGEN Inc. is a Sunnyvale, California nanobiotechnology company that engineers multifunctional, biodegradable magnetic and fluorescent nanoparticles for biomedical research, diagnostics and therapeutics. Built on its proprietary nanoparticle-imaging-delivery (NID) and MagVigen platforms, NVIGEN makes reagents and assays that capture DNA, RNA, proteins and rare cells from a single blood or tissue sample - powering liquid biopsy, NGS/multiomics sample preparation, single-cell spatial sequencing, and targeted drug and cell therapy. Its products are used by researchers at more than 40 institutions worldwide.
BreezeBio (formerly GenEdit) is a Brisbane, California-based biotechnology company that develops precision genetic medicines using its proprietary NanoGalaxy platform - a library of polymer nanoparticles capable of delivering genetic payloads like mRNA, siRNA, and CRISPR components to specific tissues without triggering immune responses. Unlike viral vectors that can only be dosed once and often provoke dangerous immune reactions, BreezeBio's non-viral approach allows repeat dosing, broad payload flexibility, and tissue selectivity across immune cells, heart, lung, and CNS. Founded in 2016 out of UC Berkeley by CEO Dr. Kunwoo Lee and CTO Dr. Hyo Min Park, the company rebranded from GenEdit in early 2026 following its $60M Series B, signaling a shift from delivery-platform licensor to full therapeutic developer with a lead program (BRZ-101) targeting Type 1 Diabetes.